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ABSTRACT Outbreaks of the emerging arbovirus chikungunya virus (CHIKV) affect
millions of individuals in Asia, Africa, and Latin America. Vector competence can be
changed dramatically by single amino acid exchanges located predominantly within
the CHIKV E1 and E2 envelope proteins, which are associated with enhanced trans-
missibility by anthropophilic Aedes mosquitoes. Commonly used reference assays for
molecular surveillance cover only a few adaptive mutations within the envelope do-
mains and have not been validated for all CHIKV genotypes. The recognized land-
scape of CHIKV adaptive mutations is thus likely incomplete. We designed two
nested reverse transcription-PCR (RT-PCR) assays that cover hot spots of viral adapta-
tion to vectors within the E1 and E2 genomic domains. Primers were designed in
conserved genomic regions to allow broad usability across CHIKV genotypes. The
sensitivity of both assays was at least equivalent to E1- and E2-based reference as-
says and robust among CHIKV genotypes at 51.4 IU/reaction (E1, 95% conﬁdence in-
terval [CI], 39.8 to 78.9) and 4.0 IU/reaction (E2, 95% CI, 2.0 to 7.4). Upon analysis of
the complete known CHIKV genomic diversity, up to 11 nucleotide mismatches with
CHIKV variants occurred under oligonucleotide binding sites of reference assays, po-
tentially limiting assay sensitivity, whereas no critical mismatches occurred in the
new assays. Speciﬁcity testing with nine alphaviruses representing all serocomplexes
showed ampliﬁcation of Mayaro virus and O’nyong-nyong virus by the E1-based as-
say, but not by the E2-based assay. The high sensitivity and speciﬁcity of the new
E2-based assay may allow its diagnostic usage in resource-limited settings. The com-
bined new assays allow improved molecular epidemiological surveillance of CHIKV
globally.
IMPORTANCE The life cycle of arboviruses relies on efﬁcient infection of and trans-
mission by arthropod vectors. Adaptation to new vectors can thus dramatically in-
crease the geographic range of an arbovirus. Several adaptive mutations enhance
chikungunya virus (CHIKV) transmissibility by different mosquito species. The appear-
ance of those adaptive mutations has led to large-scale CHIKV outbreaks in Asia, Af-
rica, and Europe. Molecular surveillance of circulating CHIKV strains for adaptive mu-
tations contributes to precise risk assessments and efﬁcient vector control and
provides new insight into the evolution of vector adaptation. Existing assays for mo-
lecular CHIKV surveillance are limited by poor coverage of known adaptive muta-
tions, low sensitivity, and cost-intensive deep sequencing approaches, preventing
universal application. We developed two highly sensitive nested RT-PCR assays that
cover hot spots of vector adaptation in CHIKV envelope domains. The new assays al-
low unprecedented molecular surveillance across all CHIKV genotypes and diagnos-
tic use in resource-limited settings globally.
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Chikungunya virus (CHIKV) is an emerging arthropod-borne virus (arbovirus) withmajor impact on public health (1). Infection with this rapidly evolving RNA virus (2)
commonly leads to severe polyarthralgia, frequently persisting for prolonged periods of
time (1, 3). CHIKV has been classiﬁed into the Asian, the East/Central/South African
(ECSA), and West African genotypes. Since 2005, CHIKV has spread extensively and is
now endemic in large parts of Africa, Asia, Oceania, and South and North America (1,
4, 5). Transmissibility of CHIKV by anthropophilic Aedes aegypti or Aedes albopictus
mosquitos can be enhanced dramatically by single amino acid exchanges (6, 7),
increasing attack rates during outbreaks and expanding outbreaks to temperate cli-
mates upon adaptation to widespread Aedes albopictus mosquitoes (1). At least 14
adaptive mutations are known, most of which are located in the genomic domains
encoding the viral envelope proteins E2 and E1 (7–13). Primary adaptations increase the
transmission by mosquito vectors, secondary adaptations provide additional ﬁtness
gains in the presence of a primary adaptation, and ﬁnally some amino acid exchanges
exert epistatic effects favoring or preventing the occurrence of primary or secondary
adaptations (5, 7). The impact of adaptive mutations is highlighted by the explosive
outbreaks caused by the CHIKV ECSA Indian Ocean lineage (IOL) affecting up to 10
million individuals during 2005 to 2007 (7, 14). Molecular epidemiological studies
revealed that the outbreak magnitude was associated with efﬁcient transmission of the
IOL by Aedes albopictus, which was mediated by two adaptive primary mutations,
E2-L210Q and E1-A226V (10). Surveillance of adaptive mutations in circulating CHIKV
lineages is therefore crucial for risk assessments and vector control strategies (15).
However, existing reverse transcription-PCR (RT-PCR) assays for molecular CHIKV sur-
veillance cover a very limited number of the known adaptive mutations. Full-genome-
based approaches are an alternative, but are cost and labor intensive, not universally
available, and technically challenging in specimens with low viral load: e.g., taken late
during the viremic phase (16, 17). To improve molecular CHIKV surveillance, we
designed new RT-PCR assays amenable for usage across all CHIKV genotypes and in
resource-limited settings.
Observations. Of the known adaptive mutations, three are located in the E1
genomic domain and eight in the E2 genomic domain (Fig. 1A). Nevertheless, the
sequence coverage of the E1 domain by GenBank entries is 2-fold higher than for
the E2 domain (Fig. 1B). The relative abundance of E1 sequences is likely due to the
biological relevance of the E1 substitution A226V, but also due to the unavailability of
suitable tools since the majority of assays commonly used for CHIKV surveillance target
small parts of the E1 domain only (Fig. 1A). Broadly used E2-based assays are hardly
available and frequently do not cover all relevant adaptive mutations (Fig. 1A).
To illustrate the three-dimensional localization of the known adaptive substitutions,
we analyzed the crystal structures of the E1 and E2 proteins. The adaptive substitutions
are not spread randomly across the CHIKV envelope proteins. Within E2, six substitu-
tions are in close three-dimensional proximity (Fig. 1C), including a small region ranging
from amino acid residues 210 to 252, which interacts with the fusion loop of E1,
mediating virus entry by fusion of viral and cellular membranes (7). Within the E1
protein, three substitutions are spread over 128 amino acid residues but are localized
in close three-dimensional proximity (Fig. 1C). The three-dimensional proximity of
adaptive substitutions may suggest that future amino acid exchanges affecting vector
competence could also be localized within these domains, which should thus be
optimal candidates for the development of assays amenable for sustainable use.
We designed two new nested RT-PCR assays targeting these CHIKV E2 and E1
domains. The assay design was done based on 1,763 GenBank entries covering at least
partially the E2 or E1 domain of CHIKV. Among other reasons, RNA secondary structures
such as those involved in viral replication and essential protein domains such as active
sites of viral enzymes or viral domains interacting with cellular components prevent
mutations from being equally distributed across virus genomes. It is thus more likely
that future mutations will occur at positions that already show genetic variation
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FIG 1 Adaptive amino acid exchanges in CHIKV and assay design. (A) Genomic localization of adaptive mutations and commonly used PCR assays. Genome
positions are shown for a CHIKV reference genome (GenBank accession no. MG967666). Positions of adaptive mutations are indicated in red and by vertical
dotted red lines at their extremities. (B) Sequence coverage and identity of the coding region of the CHIKV genome based on all available GenBank entries (18
March 2019). Coverage and identity were calculated using Geneious 9.1.8 and were visualized using R version 3.5.2. (C) Tridimensional localization of known
adaptive amino acid exchanges in the CHIKV E1 and E2 proteins. The amino acid exchanges E1-T98A (7), E1-K211E (13), E1-A226V (7), E2-G60D (9), E2-R198Q
(7), E2-L210Q (7), E2-I211T (9), E2-K233E/Q (7), E2-K234E (7), E2-K252Q (7), and E2-V264A (12) are depicted.
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between known CHIKV sequences (18, 19). Considering the complete genetic CHIKV
diversity for primer design thus increases the robustness of the assays for all known
strains but also for CHIKV strains emerging in the future. While the original intention
was to cover the complete E2-E1 region, insufﬁcient sensitivity and insufﬁcient robust-
ness across all CHIKV genotypes forced us to target smaller subgenomic domains and
test different primer combinations to achieve adequate assay sensitivity.
The oligonucleotide primers and protocol ﬁnally used cover all but one of the
known adaptive mutations in the envelope domains and are shown in Table 1. RNA of
all three CHIKV genotypes was tested with the new assays and commonly used
E1-based (20–23) or E2-based (11, 24) reference assays. The new assays ampliﬁed all
three CHIKV genotypes robustly, whereas reference assays showed limited sensitivity in
at least one genotype (Fig. 2A). Variable sensitivity of reference assays was consistent
with at least one primer used in those assays that contains possible mismatches with
one or more CHIKV genotypes at the critical 3= end of primers affecting assay sensitivity
the most (18) (see Fig. S1 in the supplemental material). We added nested PCR rounds
to ensure high sensitivity even for low-titer specimens (Fig. 2A). The exact lower limits
of detection (LOD) were assessed using RNA dilutions of the Asian CHIKV genotype
quantiﬁed using the recently developed WHO international standard. Nested PCR
improved the LOD about 4-fold for the E2-based assay, whereas the LOD of the
E1-based assay was only mildly improved. In contrast to E2, E1-based typing may thus
beneﬁt only marginally from a second round of PCR. The 95% LOD for the E1-based
assay were 63.7 IU/reaction (95% conﬁdence interval [CI], 52.2 to 118.9) in the ﬁrst
round and 51.5 IU/reaction (95% CI, 39.8 to 78.9) in the second round. The 95% LOD for
the E2-based assay were 17.4 IU/reaction (95% CI, 13.0 to 29.5) in the ﬁrst round and
4.0 IU/reaction (95% CI, 2.0 to 7.4) in the second round (Fig. 2B). Nested PCR increases
the risk of amplicon contamination. Standard precautions should therefore be applied:
e.g., handling of reagents and of ﬁrst and second round PCR products and amplicon
visualization in different areas.
In contrast to reference assays, our new assays do not contain critical mismatches to
circulating CHIKV variants under oligonucleotide binding sites (Fig. S1). Targeting
highly conserved regions ensured broad usage of our assays across CHIKV genotypes
but may increase the risk of amplifying other alphaviruses that are genetically related
to CHIKV. Although of low relevance for molecular surveillance, we assessed the
speciﬁcity of the new assays by testing nine heterologous alphaviruses representing all
alphavirus serocomplexes. The new E1-based assay showed ampliﬁcation of Mayaro
(MAYV) and O’nyong-nyong virus (ONNV) in both rounds. In contrast, the new E2-based
assay was speciﬁc for CHIKV and showed no ampliﬁcation of other alphaviruses. These







1st round (649 bp) CHIKV-E1-S1 10141–10160 GTYATCCCSTCYCCGTACGT 480
CHIKV-E1-S1B 10142–10160 TYATCCCGTCTCCGTACGT 200
CHIKV-E1-AS1 10790–10768 TTYAYMGCTCTTACCGGGTTTGT 480
CHIKV-E1-AS1B 10787–10768 AYCGCTCTTACCGGGTTTGT 200
2nd round (536 bp) CHIKV-E1-S2 10228–10248 GGMGTCTACCCATTYATGTGG 400
CHIKV-E1-S2B 10226–10248 CTGGMGTCTACCCATTTATGTGG 200
CHIKV-E1-AS2 10763–10744 ATTTGRCAGCCRAAHGGTGC 600
E2 assay
1st round (438 bp) CHIKV-E2-S1 8973–8993 CCTTGCAGCACNTAYGYGCA 600
CHIKV-E2-AS1 9410–9391 AGTGTTGGGTGRTCVGGRTA 600
2nd round (365 bp) CHIKV-E2-S2 9046–9065 CCAGAYACYCCWGAYCRCAC 600
CHIKV-E2-AS1 9410–9391 AGTGTTGGGTGRTCVGGRTA 600
aAssay sizes and primer positions are shown relative to a CHIKV reference genome (GenBank accession no.
MG967666).
bH A/C/T, M A/C, N A/C/G/T, R A/G, W A/T, V A/C/G, and Y C/T.
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FIG 2 Assay validation. (A) Determination of robustness across CHIKV genotypes. New assays (boldface) and reference assays were tested with CHIKV
RNA of the Asian, ECSA, and West African genotypes. (B) Determination of lower limits of detection (LOD) for the new PCR assays. Quantiﬁed RNA of
the Asian CHIKV genotype was diluted stepwise and was tested in eight replicates with ﬁrst-round assays. Probit analyses were done using R 3.5.2. (C)
Conservation of primer target regions among representative Mayaro (NC003417) and O’nyong-nyong (NC001512) viruses. Mismatches with the new
CHIKV assays are highlighted.
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data were consistent with high similarity of CHIKV, MAYV, and ONNV under the
E1-based assay oligonucleotide domains, whereas the oligonucleotide domains of the
E2-based assay were less conserved among these alphaviruses (Fig. 2C).
Conclusions. Molecular epidemiological surveillance of circulating CHIKV strains is
required for timely detection of adaptive mutations, which is crucial for risk assess-
ments and efﬁcient vector control (15). This need is underlined by the recent emer-
gence of a new ECSA lineage that causes large outbreaks in Kenya, India, Pakistan, and
Bangladesh. In contrast to the CHIKV ECSA IOL adapted to Aedes albopictus, the new
ECSA lineage carries two new adaptive substitutions that improve transmission by
Aedes aegypti (12). Those new adaptive mutations are located in the E1 and E2 domain
hot spots covered by our new assays, suggesting the robustness of our assays for future
adaptive mutations. The newly developed assays enhance molecular epidemiological
surveillance of CHIKV by the combination of high analytical sensitivity, robustness
across all CHIKV genotypes, and improved coverage of adaptive mutations. The high
sensitivity and speciﬁcity of the E2-based assay enable alternative usage for CHIKV
diagnostics in resource-limited settings.
Methods. (i) Primer design. Primers were designed manually relying on a data set
composed of 1,763 GenBank entries for CHIKV aligned using MAFFT in Geneious 9.1.8
after removal of ambiguous bases (https://www.geneious.com).
(ii) PCR protocols. First-round PCR assays were conducted in 25-l reaction mix-
tures using the Superscript III one-step RT-PCR system (Thermo Fisher Scientiﬁc, Darm-
stadt, Germany). Reaction mixtures were set up with 5 l RNA, 12.5 l 2 reaction
buffer, 1 g nonacetylated bovine serum albumin, and 1 l enzyme. Ampliﬁcation
involved 57°C for 30 min, followed by 95°C for 3 min and 45 cycles of 95°C for 15 s, 57°C
for 30 s, and 72°C for 48 s. Second-round PCR was performed using Platinum Taq
polymerase (Thermo Fisher Scientiﬁc) with 2.5 mM MgCl and 0.2 mM deoxynucleoside
triphosphates (dNTPs). Twenty-ﬁve-microliter reaction mixtures were set up using 2.5 l
10 reaction buffer plus 0.1 l enzyme and adding 1 l ﬁrst-round PCR product as the
template. Primers for genotype-speciﬁc boosting of sensitivity in the E1 assays were
applied at lower concentrations (Table 1).
(iii) Tested CHIKV genotypes. To determine the performance of PCR assays, RNA of
the Asian (KP003813), ECSA (MG208125), and West African (AY726732) genotypes was
tested. Before testing, viral RNA was quantiﬁed using the WHO CHIKV standard and
diluted to speciﬁc concentrations. The WHO CHIKV standard is composed of a heat-
inactivated CHIKV ECSA strain (R91064) isolated from a patient who got infected in 2006
in India. The strain was acquired from the Paul Ehrlich Institute and was used as
speciﬁed by the manufacturer. One IU is equivalent to one genome copy, and the
ofﬁcial concentration was determined by quantiﬁcation by 24 expert laboratories (25).
(iv) Speciﬁcity testing. To assess the speciﬁcity of the new RT-PCR assays, they were
tested with RNA extracted from high-titer virus stocks in the range of 106 to 107 PFU
per ml each. For speciﬁcity testing we included Barmah Forest virus, Eastern equine
encephalitis virus, MAYV, ONNV, Ross river virus, Semliki Forest virus, Sindbis virus,
Venezuelan equine encephalitis virus, and Western equine encephalitis virus.
(v) Protein structure modeling. Adaptive amino acid exchanges were manually
introduced into the translated sequence of AM258992 and modeled on a published
crystal structure (PDB ID 3N40) using SWISS-MODEL (https://swissmodel.expasy.org/).
Models were visualized with Chimera 1.13.1 (https://www.cgl.ucsf.edu/chimera/).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00295-19.
FIG S1, TIF ﬁle, 2.6 MB.
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